Business Standard

AstraZeneca-DRL patent case: Fate of Rs 2.35 bn drug to be decided today

AstraZeneca has dragged Dr Reddy's Laboratories to the court to protect its blood clot inhibitor drug Brilinta from generic competition

AstraZeneca
Premium

Sohini Das Mumbai
British drug maker AstraZeneca's lawsuit against Dr Reddy's Laboratories to block it from launching generic versions of its medicine for heart ailments will come up for hearing in the Delhi High Court on Tuesday.

AstraZeneca has dragged Dr Reddy's Laboratories to the court to protect its Rs 2.35 billion blood clot inhibitor drug Brilinta from generic competition.

AstraZeneca launched Brilinta (molecule name Ticagrelor) in the domestic market in 2012 and is now the largest selling drug in the segment.

Globally, the drug has raked in over one billion dollar in sales for the British drugmaker which is seeking to thwart

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in